Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia

Aaron E. Foster, Malcolm K. Brenner, Gianpietro Dotti

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Immunotherapy for B-cell chronic lymphocytic leukaemia (B-CLL) and other haematological malignancies may consist of passive antibody, active immunization or adoptive T-cell transfer. This chapter will focus on T-lymphocyte immunotherapy; an approach supported by earlier observations that the beneficial effects of allogeneic stem cell transplantation depend, in part, on the graft-versus-leukaemia effects mediated by these cells. One promising strategy consists of the genetic manipulation of effector T lymphocytes to express tumour-specific T-cell receptors or chimeric antigen receptors directed against surface antigens on the B-CLL cells. This methodology is now being integrated with the concept that tumour recurrence may be due to the persistence of a reservoir of more primitive and chemoresistant tumour cells, dubbed 'cancer stem cells', with self-renewal capacity. Identification and characterization of these cancer stem cells in B-CLL is crucial for the development of new anti-tumour agents, and for the identification of target antigens for cellular immunotherapy. This chapter will describe how immunotherapy may be directed to a more primitive side population of B-CLL cells.

Original languageEnglish (US)
Pages (from-to)375-389
Number of pages15
JournalBest Practice and Research: Clinical Haematology
Issue number3
StatePublished - Sep 2008


  • adoptive T-cell transfer
  • cancer stem cells
  • CD19
  • CD20
  • chimeric antigen receptor
  • chronic lymphocytic leukaemia
  • immunoglobulins
  • immunotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia'. Together they form a unique fingerprint.

Cite this